In contrast, hepatocyte-targeted drug delivery is possible using ASOs with a linked triantennary N-acetyl galactosamine (GalNAc) cluster, which is recognized with high affinity by the hepatocyte-specific asialoglycoprotein receptor.27 In line with high expression and secretion of ANGPTL4 by the liver, hepatic silencing of ANGPTL4 has been shown to effectively and safely attenuate hyperlipidemia.28,29. Here, ANGPTL4 is linked to hyperlipidemia.